Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
RCT (n=906) found greater weight reductions with all doses of cagrilintide (0.3–4.5mg) vs placebo (6.0% to 10.8% vs 3.0%, p<0.001). Weight reductions were also greater for cagrilintide 4.5mg vs liraglutide 3.0mg (10.8% vs 9.0%, p=0.03).
Source:
The Lancet
SPS commentary:
Cagrilintide is a long-acting amylin analogue currently under investigation. A related commentary notes the study has some limitations. More than three-quarters of the participants were White, with only 6% representation from Black or African American individuals. Masking of active study drugs was not possible because of differences in dispensing devices, volumes, and dose-escalation periods. Also, although it is reported that cagrilintide 4·5 mg led to 1·8% greater weight loss than with liraglutide, the comparison was not adjusted for multiplicity. Commentary concludes that despite the noted limitations, this trial’s results suggest cagrilintide is a promising new obesity treatment offering the advantage of a different mechanism of action from existing drugs, and the possibility of combining it with GLP-1 receptor agonists, depending on the results of future studies.